Creating a new sensing platform for detecting infectious diseases.
Designing a deployable and adaptable plasmonic sensing platform for infectious disease surveillance
This study is working on a new, easy-to-use testing system that can quickly and accurately detect infectious diseases like COVID-19 and its variants, helping to improve how we monitor and manage these illnesses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11143641 on NIH RePORTER |
What this research studies
This research focuses on developing a new, adaptable sensing platform that can accurately and cost-effectively test for infectious diseases, particularly the novel coronavirus and its variants. The project aims to improve upon existing diagnostic methods, such as PCR and lateral flow assays, which often struggle with either deployment ease or accuracy. By utilizing advanced techniques like catalytic surface-enhanced Raman scattering (SERS) and machine learning, the researchers hope to create a system that can detect multiple genetic biomarkers in liquid samples. This innovative approach aims to provide rapid and reliable results for better disease surveillance and management.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who may be at risk for infectious diseases, particularly those related to the novel coronavirus.
Not a fit: Patients who are not at risk for infectious diseases or those who have already been diagnosed and treated may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and accessible testing for infectious diseases, improving public health responses.
How similar studies have performed: Other research has shown promise in developing advanced diagnostic platforms, but this specific approach using SERS and machine learning is relatively novel.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Strobbia, Pietro — University of Cincinnati
- Study coordinator: Strobbia, Pietro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.